Announcement under Regulation 30 (LODR)-Investor Presentation

Investor Presentation for Q1 FY 23

27 days ago

INVESTOR PRESENTATION

Tweet

Sentiments detected

Positive 26
  • 6 30 years of Legacy Expanded its API’s portfolio to 20+

  • The company increased its Invest footprints across geography

  • The company started and with expansion and reaching various integrated play, Company is Implement geographies and expanded on the growth path.

  • ▪ Global market is expected to grow at a compound annual growth rate (CAGR) of 11.34% from 2021 to 2028.

  • ▪ The country also has a large pool of scientists and engineers with the potential to steer the industry ahead to greater heights.

  • ▪ Domestic market is expected to grow 3x in the next decade.

  • India’s domestic pharmaceutical market is estimated at US$ 65 billion by 2024 and further expand to reach US$ 120-130 billion by 2030.

  • 15 Pharma Industry Growth Trend in the overall Low Labour Cost helps to contribution of the pharma industry.

  • Estimated Government Support under the Opportunity with 1.27 tr Aatmnirbhar Bharat government is taking all the efforts to support Indian Pharma USD revenue worldwide Industry High-End Technology

  • Economy Support is in favour of Pharma leading quality R&D and efficiency companies.

  • India provides generic drugs globally & improvement over half of the global demand for various vaccines.

  • Low better R&D and lead to better and innovative cost of production, skilled labour, better quality and products better supply reliability give it a competitive advantage.

  • Research & Development Positive Impact of Pandemic as it opens more avenues for the pharma companies.

  • A play on integration and diversified product-client mix Bal Pharma well poised to deliver sustainable growth over long term

  • An Integrated Player with well Export Markets to Domestic markets to Reframing its diversified product portfolio remain key driver drive the next leap OTC business of API’s, Intermediates and of growth Formulations - Gliclazide and Ebastine - Existing products having - Domestic market with ▪ Differentiated delivery remains prominent API approval in developed respect to formulation is a system, the brands has a drivers with a new markets shall continue to big opportunity.

  • good brand recall introduction like Alfuzosin, remain the consistent Dabigatran growth driver -

  • BAL Pharma Ltd (BPL) an integrated player with Diversification across multiple geographies, multiple Therapeutic segments has created a sustainable roadmap for long term value creation.

  • Strong presence of segment spread across PAN India distributed network in and contribute a good domestic market - Further adding products in portion of revenue lifestyle disease management therapeutical Formulations areas

  • 19 Healthy Order Book & Strong Product Pipeline API (including Intermediates)

  • - Formulation manufacturing facility has got approvals from various International Regulatory Authorities including EU GMP Malta,, MCAZ Zimbabwe TFDA Tanzania, PPB Kenya, NAFDAC Nigeria, SBDMA Yemen, NDA Uganda, NDA Uganda, FDHACA Ethiopia, PMPB Malawi, FDA Philippines and MOH Sudan etc.

  • 21 Domestic Formulations: Increasing Market presence - PAN India Operations Vibrant Multispecialty ▪ 246+ Field Force; 2800+ Stockists ; 41,300+ Doctor Reach - Nutritional supplements; Anti Allergic, Anti- Fungal, Gastro, Gynecological Glyduz and Diabetes and - Presence in 8 states - 127+ Field Force; 338 + Stockists; 12,000+ Doctor Reach

  • The scheme is aimed towards pushing domestic manufacturing of key starting materials (KSMs), drug intermediates and active pharmaceutical ingredients (APIs) to reduce import dependence on such input materials

  • The objective of the scheme is to enhance India’s manufacturing ▪ BAL pharma has received approval under the PLI scheme and placed capabilities by increasing investment and production in the sector and under ‘Category C’ of the said scheme contributing to product diversification to high-value goods in the pharmaceutical sector.

  • One of the further objectives of the scheme is to - Company’s various products in API and intermediates are eligible for create global champions out of India who has the potential to grow in size 10% incentives on incremental turnover per annum and Formulations in and scale using cutting-edge technology and thereby penetrate the global Anti Diabetic and Cardiovascular diseases are eligible for 5%.

  • incentive on incremental sales (over a base year) for pharmaceutical goods covered under Category-3 will be 5% for FY 2022-23 to FY 2025- ▪ This will help the company to diversify its product portfolio, increase the 26, 4% for 2026-27 and 3% for 2027-28.

  • top line, and enhance the profitability & margin profile.

Negative 0

    Mentioned Phrases & Organizations

    Important keywords detected (20+)

    api (30)
    pharma (26)
    anti (21)
    fdf (17)
    products (16)
    manufacturing (16)
    bal (15)
    domestic (14)
    markets (12)
    pharmaceutical (12)
    india (11)
    intermediates (11)
    across (10)
    global (9)
    drugs (9)
    formulations (9)
    unit (9)
    market (9)
    statements (8)
    product (8)

    Organizations identified (10+)

    Bal Pharma (7)
    API (4)
    Gliclazide (2)
    Revenu EBITD (2)
    Bal Pharma Limited (1)
    Pan India (1)
    Bulk Actives (1)
    Prescription Drugs (1)
    II The Company (1)
    Formulation (1)

    Tables extracted (5)

    2,493
    38%38%3…
    35%30%

    Features are experimental.